Orphan drugs for rare diseases: Is it time to revisit their special market access status?

Drugs

Volumn 72, Issue 11, 2012, Pages 1437-1443

  Simoens, Steven ^a   Cassiman, David ^b   Dooms, Marc ^b   Picavet, Eline ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Cost allocation; Health services accessibility; Legislation; Orphan drugs; Reimbursement; Research and development; Willingness to pay

Indexed keywords

ORPHAN DRUG;

DISEASE SEVERITY; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG LEGISLATION; DRUG MARKETING; DRUG RESEARCH; GOVERNMENT; NONHUMAN; RARE DISEASE; REVIEW;

COST-BENEFIT ANALYSIS; EUROPEAN UNION; HEALTH CARE SECTOR; HUMANS; ORPHAN DRUG PRODUCTION; PREVALENCE; RARE DISEASES; RESEARCH;

EID: 84864198277     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11635320-000000000-00000     Document Type: Review

References (47)

1. European Commission. Regulation (EC) No 141/2000 of the European Parliament and the Council of 16 December 1999 on orphan medicinal products. Official Journal of the European Communities 2000; L 18/1 [online]. Available from URL: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2000:018: 0001:0005:en:PDF [Accessed 2012 Jun 21]
2. United States Congress. The Orphan Drug Act. CFR Title 21 Part 316 Orphan Drugs. United States Congress 1983 [online]. Available from URL: http://law.justia.com/cfr/title21/21-5.0.1.1.6.html [Accessed 2011 Apr 4]
3. Denis A, Mergaert L, Fostier C, et al. A comparative study of European rare disease and orphan drug markets. Health Pol 2010; 97: 173-9
4. Rinaldi A. Adopting an orphan. EMBO Rep 2005; 6 (6): 507-10 (Pubitemid 40973956)
5. Westermark K, Tsigkos S, Llinares J. Is it time to clarify orphan drug policies? Yes, for equity's sake. Rapid Response 10 December 2010. BMJ 2010; 341 [online]. Available from URL: http://www.bmj.com/rapid-response/2011/11/03/it- time-clarify-orphan-drug-policies-yes-equitys-sake [Accessed 2012 Jun 22]
6. Picavet E, Dooms M, Cassiman D, et al. Orphan drugs for rare diseases: grounds for special status. Drug Dev Res. In press
7. Tambuyzer E. Rare diseases, orphan drugs and their regulation: questions and misconceptions. Nat Rev Drug Discov 2010 Dec; 9 (12): 921-9
8. McCabe C, Stafinski T, Menon D. Is it time to revisit orphan drug policies? Yes, for equity's sake. BMJ 2010; 341: c4777
9. Burls A, Austin D, Moore D. Commissioning for rare diseases: view from the frontline. BMJ 2005 Oct 29; 331 (7523): 1019-21 (Pubitemid 41552457)
10. Desser AS, Gyrd-Hansen D, Olsen JA, et al. Societal views on orphan drugs: cross sectional survey of Norwegians aged 40 to 67. BMJ 2010; 341: c4715
11. National Institute for Health and Clinical Excellence. Citizens Council Report: ultra orphan drugs. London: NICE, 2004 [online]. Available from URL: http://www.nice.org.uk/niceMedia/pdf/Citizens-Council-Ultraorphan.pdf [Accessed 2012 Mar 19]
12. Nord E. The trade-off between severity of illness and treatment effect in cost-value analysis of health care. Health Policy 1993 Aug; 24 (3): 227-38 (Pubitemid 23280732)
13. Ubel PA, Loewenstein G. Distributing scarce livers: the moral reasoning of the general public. Soc Sci Med 1996 Apr; 42 (7): 1049-55 (Pubitemid 26109024)
14. McCabe C, Tsuchiya A, Claxton K, et al. Orphan drugs revisited. QJM 2006 May; 99 (5): 341-5
15. Cookson R, McCabe C, Tsuchiya A. Public healthcare resource allocation and the rule of rescue. J Med Ethics 2008; 34 (7): 540-4
16. Jonsen AR. Bentham in a box: technology assessment and health care allocation. Law Med Health Care 1986; 14 (3-4): 172-4
17. McCabe C. Balancing economic, ethical and equity concerns in orphan drugs and rare diseases. Eur J Hosp Pharm Practice 2010; 16 (4): 22-4
18. Denis A, Mergaert L, Fostier C, et al. Issues surrounding orphan disease and orphan drug policies in Europe. Appl Health Econ Health Policy 2010; 8 (5): 343-50
19. European Organisation for Rare Diseases. Inventory of access and prices of orphan drugs across Europe: a collaborative work between national alliances on rare diseases & Eurordis [online]. Available from URL: http://img.eurordis.org/newsletter/pdf/mar-2011/ERTC-13122010-YLeCam-Final.pdf [Accessed 2012 Jun 11]
20. Heemstra HE. Variations in access and use of orphan drugs among EU Member States. Eur J Hosp Pharm Practice 2010; 16 (4): 25-7
21. Barton JH, Emanuel EJ. The patents-based pharmaceutical development process: rationale, problems, and potential reforms. JAMA 2005 Oct 26; 294 (16): 2075-82 (Pubitemid 41539941)
22. Simoens S. Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet J Rare Dis 2011 Jun 17; 6: 42
23. Picavet E, Dooms M, Cassiman D, et al. Drugs for rare diseases: orphan designation status influences price. Appl Health Econ Health Policy 2011; 9 (4): 1-5
24. Hollis A. Drugs for rare diseases: paying for innovation. In: Beach C, editor. Health services restructuring in Canada: new evidence and new directions. Montreal (QC): McGill- Queen's University Press, 2006
25. Loughnot D. Potential interactions of the Orphan Drug Act and pharmacogenomics: a flood of orphan drugs and abuses? Am J Law Med 2005; 31 (2-3): 365-80 (Pubitemid 41192518)
26. Gatta G, van der Zwan JM, Casali PG, the RARECARE working group. Rare cancers are not so rare: the rare cancer burden in Europe. Eur J Cancer 2011; 47: 2493-511
27. DiMasi JA, Grabowski HG. Economics of new oncology drug development. J Clin Oncol 2007; 25 (2): 209-16 (Pubitemid 350003036)
28. Drummond MF, Wilson DA, Kanavos P, et al. Assessing the economic challenges posed by orphan drugs. Int J Technol Assess Health Care 2007; 23 (1): 36-42 (Pubitemid 46648298)
29. Ferner RE, Hughes DA. The problem of orphan drugs. BMJ 2010; 341: c6456
30. GrabowskiHG, Vernon J. The distribution of sales revenues from pharmaceutical innovation. Pharmacoeconomics 2000; 18 Suppl. 1: 21-32
31. Maeder T. The orphan drug backlash. Sci Am 2003 May; 288 (5): 80-7
32. Wellman-Labadie O, Zhou Y. The US Orphan Drug Act: rare disease research stimulator or commercial opportunity? Health Policy 2009 Dec 24; 95(2-3): 216-28
33. Ekins S, Williams AJ, Krasowski MD, et al. In silico repositioning of approved drugs for rare and neglected diseases. Drug Discov Today 2011 Apr; 16 (7-8): 298-310
34. Simoens S, Picavet E, Cassiman D, et al. What price do we pay for repurposing medicines for rare diseases? BMJ 2012 Jan 4 [online]. Available from URL: http://www.bmj.com/rapid-response/2011/11/27/re-orphan-diseases-which- onesdo- we-adopt [Accessed 2012 Jun 22]
35. Schey C, Milanova T, Hutchings A. Estimating the budget impact of orphan medicines in Europe: 2010-2020. Orphanet J Rare Dis 2011 Sep 27; 6: 62
36. Danzon PM. At what price? Nature 2007 Sep 13; 449 (7159): 176-9 (Pubitemid 47402358)
37. Maurer SM. Choosing the right incentive strategy for research and development in neglected diseases. Bull World Health Organ 2006 May; 84 (5): 376-81
38. McCabe C, Edlin R, Round J. Economic considerations in the provision of treatments for rare diseases. Adv Exp Med Biol 2010; 686: 211-22
39. Posada de la Paz M, Groft SC, editors. Rare diseases epidemiology. Advances in Experimental Medicine and Biology - Vol. 686. Dordrecht: Springer Science+Business Media, 2010
40. Drummond M, Evans B, LeLorier J, et al. Evidence and values: requirements for public reimbursement of drugs for rare diseases: a case study in oncology. Can J Clin Pharmacol 2009; 16(2): e273-81
41. Claxton KP, Sculpher MJ. Using value of information analysis to prioritise health research: some lessons from recent UK experience. Pharmacoeconomics 2006; 24 (11): 1055-68 (Pubitemid 44683363)
42. Tunis SR, Pearson SD. Coverage options for promising technologies: Medicare's 'coverage with evidence development'. Health Aff (Millwood) 2006 Sep; 25 (5): 1218-30 (Pubitemid 44497620)
43. Stafinski T, McCabe CJ, Menon D. Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems. Pharmacoeconomics 2010; 28 (2): 113-42
44. Owen A, Sprinks J, Meehan A, et al. A new model to evaluate the long-term cost effectiveness of orphan and highly specialised drugs following listing on the Australian Pharmaceutical Benefits Scheme: the Bosentan Patient Registry. J Med Econ 2008; 11: 235-43
45. Cook JP, Vernon JA, Manning R. Pharmaceutical risksharing agreements. Pharmacoeconomics 2008; 26 (7): 551-6
46. Connock M, Juarez-Garcia A, Frew E. A systematic review of the clinical effectiveness and cost-effectiveness of enzyme replacement therapies for Fabry's disease and mucopolysaccharidosis type 1. Health Technol Assess 2006; 10 (20): iii-113
47. McCabe C, Claxton K, Tsuchiya A.Orphan drugs and theNHS: should we value rarity? BMJ 2005 Oct 29; 331 (7523): 1016-9 (Pubitemid 41552456)